541 related articles for article (PubMed ID: 20151821)
1. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
2. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Do Cao C; Wémeau JL
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density in women receiving thyroxine suppressive therapy for differentiated thyroid carcinoma.
Chen CH; Chen JF; Yang BY; Liu RT; Tung SC; Chien WY; Lu YC; Kuo MC; Hsieh CJ; Wang PW
J Formos Med Assoc; 2004 Jun; 103(6):442-7. PubMed ID: 15278189
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
Łacka K
Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
[TBL] [Abstract][Full Text] [Related]
5. The effect of long-term thyroid-stimulating hormone suppressive therapy on the cognitive function of elderly patients with differentiated thyroid carcinoma.
Moon JH; Ahn S; Seo J; Han JW; Kim KM; Choi SH; Lim S; Park YJ; Park DJ; Kim KW; Jang HC
J Clin Endocrinol Metab; 2014 Oct; 99(10):3782-9. PubMed ID: 25029415
[TBL] [Abstract][Full Text] [Related]
6. Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer.
Gazdag A; Nagy EV; Erdei A; Bodor M; Berta E; Szabó Z; Jenei Z
J Endocrinol Invest; 2015 Feb; 38(2):133-42. PubMed ID: 25194423
[TBL] [Abstract][Full Text] [Related]
7. [L-thyroxine therapy in differentiated thyroid carcinoma: criteria for evaluation of TSH suppression].
Kowalczyk P; Roskosz J; Jurecka-Tuleja B; Gubała E; Czernik E; Jarzab B
Wiad Lek; 2001; 54(5-6):268-76. PubMed ID: 11556209
[TBL] [Abstract][Full Text] [Related]
8. [Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
Miyakawa M
Nihon Rinsho; 2007 Nov; 65(11):2073-7. PubMed ID: 18018573
[TBL] [Abstract][Full Text] [Related]
9. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
10. Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma.
Wang LY; Smith AW; Palmer FL; Tuttle RM; Mahrous A; Nixon IJ; Patel SG; Ganly I; Fagin JA; Boucai L
Thyroid; 2015 Mar; 25(3):300-7. PubMed ID: 25386760
[TBL] [Abstract][Full Text] [Related]
11. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring.
Mercuro G; Panzuto MG; Bina A; Leo M; Cabula R; Petrini L; Pigliaru F; Mariotti S
J Clin Endocrinol Metab; 2000 Jan; 85(1):159-64. PubMed ID: 10634380
[TBL] [Abstract][Full Text] [Related]
12. Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma.
Wang PW; Wang ST; Liu RT; Chien WY; Tung SC; Lu YC; Chen HY; Lee CH
J Clin Endocrinol Metab; 1999 Dec; 84(12):4549-53. PubMed ID: 10599717
[TBL] [Abstract][Full Text] [Related]
13. Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement.
Spencer CA; LoPresti JS; Fatemi S; Nicoloff JT
Thyroid; 1999 May; 9(5):435-41. PubMed ID: 10365673
[TBL] [Abstract][Full Text] [Related]
14. The role of thyrotropin suppression in patients with differentiated thyroid carcinoma.
Deasy J; Prichard RS; Evoy D; McDermott EW
Ir Med J; 2010; 103(7):202-5. PubMed ID: 20845598
[TBL] [Abstract][Full Text] [Related]
15. Is the incidence of differentiated thyroid cancer increased in patients with thyrotropin-secreting adenomas? Report of three cases from a large consecutive series.
Perticone F; Pigliaru F; Mariotti S; Deiana L; Furlani L; Mortini P; Losa M
Thyroid; 2015 Apr; 25(4):417-24. PubMed ID: 25647054
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the nocturnal serum thyrotropin (TSH) surge, as assessed by TSH ultrasensitive assay, in patients receiving long term L-thyroxine suppression therapy and in patients with various thyroid disorders.
Bartalena L; Martino E; Falcone M; Buratti L; Grasso L; Mammoli C; Pacchiarotti A; Aghini-Lombardi F; Balzano S; Pinchera A
J Clin Endocrinol Metab; 1987 Dec; 65(6):1265-71. PubMed ID: 3680483
[TBL] [Abstract][Full Text] [Related]
17. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
18. Degree of thyrotropin suppression in differentiated thyroid cancer without recurrence or metastases.
Kamel N; Güllü S; Dağci Ilgin S; Corapçioğlu D; Tonyukuk Cesur V; Uysal AR; Başkal N; Erdoğan G
Thyroid; 1999 Dec; 9(12):1245-8. PubMed ID: 10646665
[TBL] [Abstract][Full Text] [Related]
19. Trabecular bone deterioration in differentiated thyroid cancer: Impact of long-term TSH suppressive therapy.
Hawkins Carranza F; Guadalix Iglesias S; Luisa De Mingo Domínguez M; Martín-Arriscado Arroba C; López Álvarez B; Allo Miguel G; Martínez Díaz-Guerra G
Cancer Med; 2020 Aug; 9(16):5746-5755. PubMed ID: 32583973
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of TSH suppression using a 3d-generation TSH assay: diagnostic and therapeutic consequences].
Exer P; Staub JJ; Zulewski H; Müller B; Kunz M; Huber P
Schweiz Med Wochenschr; 1992 Dec; 122(51-52):1964-7. PubMed ID: 1475661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
